“There’s no hidingthat investing in Neuren has its risks, that’s the nature of drug development, but external analystvaluations of the business today are multiples of the current share price with one at $3.93 and ourinternal modelling is higher again.”
Ann: AGM Chairman's Address and CEO Presentation, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.70 |
Change
0.220(1.33%) |
Mkt cap ! $2.104B | |||
| Open | High | Low | Value | Volume |
| $16.65 | $16.90 | $16.33 | $5.569M | 332.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1333 | $16.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.78 | 30 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |